Clinical trials: Remission of Ulcerative Colitis
Prospective Study, Ulcerative Colitis in Remission
A Multicenter Prospective Cohort Study on the Clinical Prognosis of Ulcerative Colitis
Mucosal healing or histological remission is an important target for the treatment of inflammatory bowel disease. In this study, patients with mucosal healing are defined as a control group, observing their clinical outcomes for…
- Trial name
- NCT03698812
- Testing
- Colonoscope
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Pediatric Ulcerative Colitis in Remission
Oral Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis
The purpose of this study is to evaluate whether FMT by frozen stool capsules in pediatric UC patients in remission after corticosteroid treatment, can modify their dysbiotic gut microbiota by increasing the richness of their…
- Trial name
- T-FORE (NCT05202990)
- Testing
- Fecal Microbiota Transplantation by Stool capsules, Fecal Microbiota Transplantation by Intra-rectal enemas
- Where
- 3 sites in France
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Disease Activity, Remission of Ulcerative Colitis
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis
Specialized pro-resolving mediators (SPMs), which are typically thought to be formed via consecutive steps of oxidation of polyenoic fatty acids, have been shown to suppress inflammation and promote timely resolution of…
- Conditions
- Disease Activity, Remission of Ulcerative Colitis, Ulcerative Colitis Flare
- Trial name
- NCT06652464
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Inflammatory Bowel Disease, Crohn Disease
Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With Inflammatory Bowel Disease
We hypothesize that the number of needed endoscopic procedure performed at IBD patients (adult and children), can be reduced by using an individualized algorithm of symptoms, blood and faecal biomarkers.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT01861288
- Where
- Denmark
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Ulcerative Colitis
Efficacy of Golimumab in Maintaining Deep Remission in UC Patients in Prolonged Remission With Infliximab
This study monitors the efficacy and safety of Golimumab in maintaining deep remission and quality of life in Ulcerative Colitis patients in deep prolonged remission with Infliximab.
- Trial name
- Switch (NCT02868398)
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Evangelismos Hospital
IBS, Ulcerative Colitis, Active
Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
- Conditions
- IBS, Ulcerative Colitis, Active, Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms), Healthy Controls
- Trial name
- NCT02421705
- Testing
- Sample collection
- Where
- Belgium
- Volunteers
- 99,999,999 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Aloe Vera Gel, Proctosigmoiditis, Remission, Trial, Ulcerative Colitis (UC)
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ENEMA ALOE VERA GEL IN ACTIVE ULCERATIVE PROCTOSIGMOIDITIS.
Aloe vera is used for the treatment of inflammatory bowel disease (IBD), but no data are present in regard the gel formulation as topical therapy in active ulcerative colitis.
- Trial name
- NCT04753775
- Testing
- Aloe vera gel
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Ospedale Sandro Pertini, Roma
Ulcerative Colitis
PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation limited to colonic mucosa. Its pathogenesis is not still clear, even if a multifactorial aetiology has been advocated.
- Trial name
- PROREM UC (NCT03415711)
- Testing
- VSL#3®, Mesalamine
- Where
- Italy
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- VSL Pharmaceuticals